Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check2 days agoChange DetectedUpdated the page from Revision v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check17 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous specific locations across various countries and the introduction of new medical terminology related to medullary thyroid gland carcinoma. Additionally, a key reference to a Phase 3 trial of selpercatinib has been included.SummaryDifference17%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check45 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.